Sander R. Piersma

Sander R. Piersma

Auto-generated profile, based on publicly available information

Sander R. Piersma

Amsterdam UMC location Vrije Universiteit Amsterdam, OncoProteomics Laboratory, Department of Medical Oncology, van der Boechorststraat 6B, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2010 in Journal of Proteome Research
Verified
Journal Article
Closed access
SPSander R. Piersma
Sander R. Piersma
UFUlrike Fiedler
Ulrike Fiedler
SSSimone Span
Simone Span
ALAndreas Lingnau
Andreas Lingnau
TPThang V. Pham
Thang V. Pham
CJConnie R. Jiménez
Connie R. Jiménez

1 January 2021 in Circulation: Heart Failure
Verified
Journal Article
Open access
PDF file
MSMaike Schuldt
Maike Schuldt
JPJiayi Pei
Jiayi Pei
MHMagdalena Harakalova
Magdalena Harakalova
LDLarissa Dorsch
Larissa Dorsch
SSSaskia Schlossarek
Saskia Schlossarek
DKDiederik W.D. Kuster
Diederik W.D. Kuster
Background: Hypertrophic cardiomyopathy (HCM) is the most common genetic heart disease. While ≈50% of patients with HCM carry a sarcomere gene mutation (sarcomere mutation-positive, HCM SMP ), the genetic background is unknown in the other half of the patients (sarcomere mutation-negative, HCM SMN ). Genotype-specific differences have been reported in cardiac function. Moreover, HCM SMN patients have later disease onset and a better prognosis than HCM SMP patients. To define if genotype-specific derailments at the protein level may explain the heterogeneity in disease development, we performed a proteomic analysis in cardiac tissue from a clinically well-phenotyped HCM patient group. Methods: A proteomics screen was performed in cardiac tissue from 39 HCM SMP patients, 11HCM SMN patients, and 8 nonfailing controls. Patients with HCM had obstructive cardiomyopathy with left ventricular outflow tract obstruction and diastolic dysfunction. A novel MYBPC3 2373insG mouse model was used to confirm functional relevance of our proteomic findings. Results: In all HCM patient samples, we found lower levels of metabolic pathway proteins and higher levels of extracellular matrix proteins. Levels of total and detyrosinated α-tubulin were markedly higher in HCM SMP than in HCM SMN and controls. Higher tubulin detyrosination was also found in 2 unrelated MYBPC3 mouse models and its inhibition with parthenolide normalized contraction and relaxation time of isolated cardiomyocytes. Conclusions: Our findings indicate that microtubules and especially its detyrosination contribute to the pathomechanism of patients with HCM SMP . This is of clinical importance since it represents a potential treatment target to improve cardiac function in patients with HCM SMP , whereas a beneficial effect may be limited in patients with HCM SMN .

1 April 2020 in Genomics, Proteomics & Bioinformatics
Verified
Journal Article
Open access
TZTiansheng Zhu
Tiansheng Zhu
YZYi Zhu
Yi Zhu
YXYue Xuan
Yue Xuan
HGHuanhuan Gao
Huanhuan Gao
XCXue Cai
Xue Cai
TGTiannan Guo
Tiannan Guo
To address the increasing need for detecting and validating protein biomarkers in clinical specimens, mass spectrometry (MS)-based targeted proteomic techniques, including the selected reaction monitoring (SRM), parallel reaction monitoring (PRM), and massively parallel data-independent acquisition (DIA), have been developed. For optimal performance, they require the fragment ion spectra of targeted peptides as prior knowledge. In this report, we describe a MS pipeline and spectral resource to support targeted proteomics studies for human tissue samples. To build the spectral resource, we integrated common open-source MS computational tools to assemble a freely accessible computational workflow based on Docker. We then applied the workflow to generate DPHL, a comprehensive DIA pan-human library, from 1096 data-dependent acquisition (DDA) MS raw files for 16 types of cancer samples. This extensive spectral resource was then applied to a proteomic study of 17 prostate cancer (PCa) patients. Thereafter, PRM validation was applied to a larger study of 57 PCa patients and the differential expression of three proteins in prostate tumor was validated. As a second application, the DPHL spectral resource was applied to a study consisting of plasma samples from 19 diffuse large B cell lymphoma (DLBCL) patients and 18 healthy control subjects. Differentially expressed proteins between DLBCL patients and healthy control subjects were detected by DIA-MS and confirmed by PRM. These data demonstrate that the DPHL supports DIA and PRM MS pipelines for robust protein biomarker discovery. DPHL is freely accessible at https://www.iprox.org/page/project.html?id=IPX0001400000.

1 January 2013 in Proteome Science
Verified
Journal Article
Open access
PDF file
SPSander R Piersma
Sander R Piersma
MWMarc O Warmoes
Marc O Warmoes
MWMeike de Wit
Meike de Wit
IRInge de Reus
Inge de Reus
JKJaco C Knol
Jaco C Knol
CJConnie R Jimenez
Connie R Jimenez
SDS-PAGE followed by in-gel digestion (IGD) is a popular workflow in mass spectrometry-based proteomics. In GeLC-MS/MS, a protein lysate of a biological sample is separated by SDS-PAGE and each gel lane is sliced in 5–20 slices which, after IGD, are analyzed by LC-MS/MS. The database search results for all slices of a biological sample are combined yielding global protein identification and quantification for each sample. In large scale GeLC-MS/MS experiments the manual processing steps including washing, reduction and alkylation become a bottleneck. Here we introduce the whole gel (WG) procedure where, prior to gel slice cutting, the processing steps are carried out on the whole gel. In two independent experiments human HCT116 cell lysate and mouse tumor tissue lysate were separated by 1D SDS PAGE. In a back to back comparison of the IGD procedure and the WG procedure, both protein identification (>80% overlap) and label-free protein quantitation (R2=0.94) are highly similar between procedures. Triplicate analysis of the WG procedure of both HCT116 cell lysate and formalin-fixed paraffin embedded (FFPE) tumor tissue showed identification reproducibility of >88% with a CV<20% on protein quantitation. The whole gel procedure allows for reproducible large-scale differential GeLC-MS/MS experiments, without a prohibitive amount of manual processing and with similar performance as conventional in-gel digestion. This procedure will especially enable clinical proteomics for which GeLC-MS/MS is a popular workflow and sample numbers are relatively high.

1 December 2017 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
IBIrene Bijnsdorp
Irene Bijnsdorp
OMOlga Maxouri
Olga Maxouri
AKAarzo Kardar
Aarzo Kardar
TSTim Schelfhorst
Tim Schelfhorst
SPSander R. Piersma
Sander R. Piersma
CJConnie R Jimenez
Connie R Jimenez
Extracellular vesicles (EVs) secreted by prostate cancer (PCa) cells contain specific biomarkers and can be isolated from urine. Collection of urine is not invasive, and therefore urinary EVs represent a liquid biopsy for diagnostic and prognostic testing for PCa. In this study, we optimised urinary EV isolation using a method based on heat shock proteins and compared it to gold‐standard ultracentrifugation. The urinary EV isolation protocol using the Vn96‐peptide is easier, time convenient (≈1.5 h) and no special equipment is needed, in contrast to ultracentrifugation protocol (>3.5 h), making this protocol clinically feasible. We compared the isolated vesicles of both ultracentrifugation and Vn96‐peptide by proteome profiling using mass spectrometry‐based proteomics (n = 4 per method). We reached a depth of >3000 proteins, with 2400 proteins that were commonly detected in urinary EVs from different donors. We show a large overlap (>85%) between proteins identified in EVs isolated by ultracentrifugation and Vn96‐peptide. Addition of the detergent NP40 to Vn96‐peptide EV isolations reduced levels of background proteins and highly increased the levels of the EV‐markers TSG101 and PDCD6IP, indicative of an increased EV yield. Thus, the Vn96‐peptide‐based EV isolation procedure is clinically feasibly and allows large‐scale protein profiling of urinary EV biomarkers.

1 September 2015 in Journal of Proteomics
Verified
Journal Article
Closed access
SPSander R. Piersma
Sander R. Piersma
JKJaco C. Knol
Jaco C. Knol
IRInge de Reus
Inge de Reus
MLMariette Labots
Mariette Labots
BSBharath Sampadi
Bharath Sampadi
CJConnie R Jimenez
Connie R Jimenez